Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Coremed has entered into a joint venture partnership with two of China's largest pharmaceutical companies, Shanghai-based Fosun and Xuzhou-based Wanbang. The three companies intend to develop Alveair inhalable insulin through all phases of clinical trials and product commercialization.
Subscribe to our email newsletter
“The significance of this joint venture is that it now links a low-cost producer, with a huge manufacturing capacity,” Said Dr Frank Leung, Coremed’s founder. “Combined, this will position Coremed to one day serve global biopharmaceutical markets.”
Fosun’s pharma division is recognized for its drug manufacturing, diagnostic products, medical devices, R&D and logistics. Whilst Wanbang is the largest manufacturer of insulin in China, with dominant market share in a country that has an estimated 40-50 million diabetics.
Founded in 1994, Coremed is exclusively dedicated to the development of alternate insulin delivery.